Lombard Medical, Inc. (EVARF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lombard Medical, Inc. (EVARF) with AI Score 47/100 (Weak). Lombard Medical, Inc. specializes in developing and marketing endovascular stent-grafts for aortic aneurysm repair. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Lombard Medical, Inc. (EVARF) Healthcare & Pipeline Overview
Lombard Medical, Inc. focuses on endovascular stent-grafts, particularly Aorfix for complex aortic aneurysms. With a global presence and direct sales model, the company competes in the medical device industry, facing challenges in a market with established players and stringent regulatory requirements, reflected in its negative profit margin.
Investment Thesis
Lombard Medical, Inc. presents a focused investment opportunity within the medical device sector, specifically in the endovascular aneurysm repair market. The company's Aorfix stent-graft addresses a niche segment of AAAs with challenging anatomies, potentially offering a competitive advantage. However, the company's negative profit margin of -255.0% and small market capitalization raise concerns about its financial sustainability. Growth catalysts include expanding market penetration in existing geographies and potential regulatory approvals in new markets. Investors should carefully consider the company's financial position, competitive landscape, and regulatory hurdles before making investment decisions. The company's beta of 0.64 suggests lower volatility than the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with potential for high growth but also significant risk.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -255.0% signals significant operational challenges and potential financial instability.
- Gross Margin of 7.8% suggests limited pricing power and high cost of goods sold.
- Beta of 0.64 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.
Competitors & Peers
Strengths
- Specialized Aorfix stent-graft for complex anatomies.
- Proprietary delivery systems for precise placement.
- Direct sales force and distributor network.
- Focus on state-owned and government-owned hospitals.
Weaknesses
- Negative profit margin and small market capitalization.
- Limited product portfolio compared to larger competitors.
- Reliance on a few key products.
- Dependence on regulatory approvals for market expansion.
Catalysts
- Upcoming: Potential regulatory approvals in new geographic markets, expanding market access.
- Ongoing: Continued adoption of Aorfix stent-graft among vascular surgeons.
- Ongoing: Expansion of clinical education and training programs.
Risks
- Potential: Increased competition from larger medical device companies.
- Potential: Delays in regulatory approvals.
- Ongoing: Negative profit margin and financial instability.
- Ongoing: Limited liquidity due to OTC listing.
- Potential: Technological obsolescence.
Growth Opportunities
- Expansion into Emerging Markets: Lombard Medical has the opportunity to expand its geographic footprint into emerging markets with growing healthcare infrastructure and increasing awareness of endovascular procedures. These markets often present less competition and unmet clinical needs, allowing Lombard Medical to gain market share. Successful entry into these markets requires navigating local regulatory requirements and establishing distribution networks. The global market for endovascular aneurysm repair is projected to grow, offering a substantial opportunity for Lombard Medical to capitalize on this trend.
- Product Line Expansion: Lombard Medical can expand its product line to address a broader range of aortic diseases and anatomies. This could involve developing new stent-grafts, delivery systems, or adjunctive therapies. Expanding the product portfolio would allow Lombard Medical to target a larger patient population and increase its revenue streams. This strategy requires significant investment in research and development, as well as clinical trials to demonstrate safety and efficacy.
- Strategic Partnerships and Acquisitions: Lombard Medical could pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, or technological capabilities. Partnering with larger medical device companies could provide access to established distribution networks and marketing resources. Acquiring complementary technologies or companies could accelerate product development and market entry. Successful partnerships and acquisitions require careful due diligence and integration planning.
- Focus on Clinical Education and Training: Lombard Medical can invest in clinical education and training programs to increase awareness and adoption of its products among vascular surgeons and interventional radiologists. Providing hands-on training and educational resources can help physicians overcome the learning curve associated with new technologies and techniques. This strategy can lead to increased product utilization and improved clinical outcomes. Clinical education and training programs can be delivered through workshops, conferences, and online platforms.
- Development of Next-Generation Stent-Graft Technology: Lombard Medical can invest in research and development to develop next-generation stent-graft technology with improved performance, durability, and ease of use. This could involve incorporating new materials, designs, or delivery systems. Developing innovative technology can provide a competitive advantage and attract new customers. This strategy requires significant investment in research and development, as well as clinical trials to demonstrate the superiority of the new technology.
Opportunities
- Expansion into emerging markets.
- Product line expansion to address broader range of aortic diseases.
- Strategic partnerships and acquisitions.
- Development of next-generation stent-graft technology.
Threats
- Competition from larger, established medical device companies.
- Stringent regulatory requirements and potential delays in approvals.
- Technological obsolescence.
- Economic downturns and healthcare budget constraints.
Competitive Advantages
- Proprietary Aorfix stent-graft designed for complex anatomies.
- Specialized delivery systems for precise stent-graft placement.
- Established relationships with state-owned and government-owned hospitals.
- Intellectual property protection for key technologies.
About EVARF
Founded in 2000 and headquartered in Didcot, UK, Lombard Medical, Inc. is a medical technology company focused on designing, manufacturing, and marketing advanced endovascular stent-grafts for the repair of aortic aneurysms. The company's flagship product, Aorfix, is a unique endovascular stent-graft specifically engineered for the treatment of abdominal aortic aneurysms (AAAs) with significant angulation at the neck of the aneurysm, up to 90 degrees. This addresses a critical need in treating patients with challenging anatomies. In addition to Aorfix, Lombard Medical offers the Altura endovascular stent graft system, designed for standard AAA anatomies. The company also provides specialized delivery systems, including the Aorflex delivery system for precise Aorfix placement and the IntelliFlex LP delivery system to enhance control during deployment. Lombard Medical distributes its products through a direct sales force and distributors, primarily targeting state-owned or government-owned hospitals across the United States, the United Kingdom, Germany, Japan, and other international markets. The company operates in a competitive landscape, facing established medical device companies.
What They Do
- Develops endovascular stent-grafts for aortic aneurysm repair.
- Manufactures Aorfix stent-graft for complex abdominal aortic aneurysms.
- Markets Aorfix and Altura stent-graft systems globally.
- Provides Aorflex and IntelliFlex delivery systems for precise stent-graft placement.
- Sells products directly and through distributors.
- Targets state-owned and government-owned hospitals.
Business Model
- Develops and manufactures endovascular stent-grafts.
- Sells products directly through a sales force and distributors.
- Generates revenue from stent-graft sales for aortic aneurysm repair.
- Focuses on state-owned and government-owned hospitals as primary customers.
Industry Context
Lombard Medical operates within the global medical device industry, specifically targeting the endovascular aneurysm repair (EVAR) market. This market is driven by an aging population, increasing prevalence of aortic aneurysms, and technological advancements in minimally invasive procedures. The competitive landscape includes larger, established medical device companies with broader product portfolios. Lombard Medical differentiates itself with its Aorfix stent-graft, designed for complex anatomies. The industry is subject to stringent regulatory requirements and ongoing technological innovation.
Key Customers
- State-owned hospitals
- Government-owned hospitals
- Vascular surgeons
- Interventional radiologists
Financials
Chart & Info
Lombard Medical, Inc. (EVARF) stock price: Price data unavailable
Latest News
No recent news available for EVARF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVARF.
Price Targets
Wall Street price target analysis for EVARF.
MoonshotScore
What does this score mean?
The MoonshotScore rates EVARF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kurt Lemvigh
CEO
Kurt Lemvigh serves as the Chief Executive Officer of Lombard Medical, Inc. His background includes experience in the medical device industry, with a focus on commercialization and market development. Prior to joining Lombard Medical, he held leadership positions at various medical technology companies, where he was responsible for driving revenue growth and expanding market share. He has a proven track record of successfully launching new products and building high-performing teams. His expertise lies in strategic planning, sales and marketing, and business development within the healthcare sector.
Track Record: Since assuming the role of CEO at Lombard Medical, Kurt Lemvigh has focused on streamlining operations, expanding the company's geographic reach, and driving adoption of the Aorfix stent-graft. Key initiatives include strengthening the sales force, establishing new distribution partnerships, and investing in clinical education programs. Under his leadership, the company has faced challenges related to profitability and market competition. His focus remains on achieving sustainable growth and improving financial performance.
EVARF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lombard Medical may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes.
- Established history in the medical device industry.
- Proprietary technology and products.
- Global presence and distribution network.
- Experienced management team.
Common Questions About EVARF
What does Lombard Medical, Inc. do?
Lombard Medical, Inc. is a medical technology company that develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms. Their main product, Aorfix, is designed for abdominal aortic aneurysms with angulation at the neck, addressing a challenging anatomical subset. They also offer the Altura system for standard anatomies. The company sells these products globally through a direct sales force and distributors, primarily targeting state-owned and government-owned hospitals. Lombard Medical focuses on providing minimally invasive solutions for aortic disease.
What do analysts say about EVARF stock?
As of 2026-03-17, formal analyst ratings for EVARF are unavailable, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio, are not meaningful due to the company's negative profitability. Growth considerations revolve around expanding market share, securing regulatory approvals, and achieving financial stability. Investors should conduct thorough due diligence and assess the company's financial health and competitive position before making any investment decisions. The absence of analyst coverage highlights the speculative nature of this investment.
What are the main risks for EVARF?
The main risks for Lombard Medical, Inc. include its negative profit margin, indicating financial instability and potential difficulty in sustaining operations. Competition from larger medical device companies with greater resources poses a significant threat. Delays in regulatory approvals for new products or market expansion could hinder growth. As an OTC-listed stock, EVARF faces liquidity risks and limited regulatory oversight. Technological obsolescence is also a concern, as advancements in endovascular aneurysm repair could render existing products less competitive. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for EVARF?
Lombard Medical, Inc. (EVARF) currently holds an AI score of 47/100, indicating low score. Key strength: Specialized Aorfix stent-graft for complex anatomies.. Primary risk to monitor: Potential: Increased competition from larger medical device companies.. This is not financial advice.
How frequently does EVARF data refresh on this page?
EVARF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EVARF's recent stock price performance?
Recent price movement in Lombard Medical, Inc. (EVARF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized Aorfix stent-graft for complex anatomies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EVARF overvalued or undervalued right now?
Determining whether Lombard Medical, Inc. (EVARF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EVARF?
Before investing in Lombard Medical, Inc. (EVARF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.